best prostate cancer doctor

New roadmap developed to genetically test for hereditary prostate cancer

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2018-01-09T08:50:54+00:00 January 9th, 2018|

CMS Announces Increase To ASC Payment For HIFU Prostate Ablation

SonaCare Medical Reports That Medicare recognizes HIFU prostate ablation as a device-intensive procedure driving new ASC payment going into effect on or after October 1, 2017 CHARLOTTE, N.C., Sept. 20, 2017 SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to announce an increase in Medicare payment for prostate HIFU ablation in the Ambulatory Surgical Center (ASC) setting. In the October 2017 update of the ASC Payment System, the Centers for Medicare and Medicaid Services (CMS) indicated that the ASC payment status for C9747, the code used to bill for HIFU ablation of prostate tissue, now recognizes HIFU as a "device-intensive procedure". The new typical ASC payment level is $5,444.89, as compared to the approximately $4,000 payment amount which went [...]

2017-12-13T13:37:18+00:00 November 14th, 2017|

Common Prostate Cancer Therapy May Trigger Dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) -- a testosterone-lowering therapy and a common treatment for the disease -- and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their previous studies have shown men who undergo ADT may be at an increased risk of dementia, including Alzheimer's disease, compared to men who were not treated with the therapy. This new analysis -- the largest of its kind ever performed on this topic -- shows that all existing studies taken together support the link to dementia and show a possible link to Alzheimer's. The findings are published this week in Prostate Cancer and Prostatic Diseases. "Since [...]

2017-12-13T13:37:20+00:00 April 4th, 2017|